239 related articles for article (PubMed ID: 33101774)
1. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Drakaki A; Dhillon PK; Wakelee H; Chui SY; Shim J; Kent M; Degaonkar V; Hoang T; McNally V; Luhn P; Gutzmer R
Oncoimmunology; 2020 Oct; 9(1):1824645. PubMed ID: 33101774
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study.
Sadetsky N; Chuo CY; Davidoff AJ
Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1233-1241. PubMed ID: 34145696
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
Lester J; Escriu C; Khan S; Hudson E; Mansy T; Conn A; Chan S; Powell C; Brock J; Conibear J; Nelless L; Nayar V; Zhuo X; Durand A; Amin A; Martin P; Zhang X; Pawar V
BMC Cancer; 2021 May; 21(1):515. PubMed ID: 33962574
[TBL] [Abstract][Full Text] [Related]
4. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Ge W; Wu N; Jalbert JJ; Quek RGW; Liu J; Rietschel P; Pouliot JF; Harnett J; Hsu ML; Feliciano JL
Cancer Manag Res; 2022; 14():3191-3202. PubMed ID: 36415537
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
7. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy.
Goldschmidt JH; Chou LN; Chan PK; Chen L; Robert N; Kinsey J; Pitts K; Nestor M; Rock EP; Lazarus HM
Cancer Med; 2023 Nov; 12(22):20783-20797. PubMed ID: 37962239
[TBL] [Abstract][Full Text] [Related]
9. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH
J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328
[TBL] [Abstract][Full Text] [Related]
10. Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer.
Zhang Y; Doran C; Le TK; Dreyfus B; Kola N; Sylvester BE; Lal L; Penrod JR; Meadows Shropshire S
Future Oncol; 2022 Dec; 18(40):4509-4523. PubMed ID: 36942686
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
Sorial MN; Huynh JP; Azzoli CG; Liauw JC; Brunault RD; Collins CM; Zullo AR
Eur J Cancer; 2021 Mar; 145():234-244. PubMed ID: 33431285
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
Geynisman DM; Broughton E; Hao Y; Zhang Y; Le T; Huo S
Urol Oncol; 2022 May; 40(5):195.e1-195.e11. PubMed ID: 34906410
[TBL] [Abstract][Full Text] [Related]
13. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
John A; Shah RA; Wong WB; Schneider CE; Alexander M
Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
[TBL] [Abstract][Full Text] [Related]
14. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.
Maslov DV; Tawagi K; Kc M; Simenson V; Yuan H; Parent C; Bamnolker A; Goel R; Blake Z; Matrana MR; Johnson DH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226279
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.
Izawa N; Shiokawa H; Onuki R; Hamaji K; Morikawa K; Saji H; Ohashi H; Kasugai S; Hayakawa N; Ohara T; Sunakawa Y
ESMO Open; 2022 Apr; 7(2):100415. PubMed ID: 35247869
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
John A; Yang B; Shah R
Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC; Mezquita L; Long N; Rizvi H; Auclin E; Ni A; Martínez-Bernal G; Ferrara R; Lai WV; Hendriks LEL; Sabari JK; Caramella C; Plodkowski AJ; Halpenny D; Chaft JE; Planchard D; Riely GJ; Besse B; Hellmann MD
J Clin Oncol; 2018 Oct; 36(28):2872-2878. PubMed ID: 30125216
[TBL] [Abstract][Full Text] [Related]
18. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment: A Systematic Review and Meta-analyses.
Lin EP; Hsu CY; Berry L; Bunn P; Shyr Y
JAMA Netw Open; 2022 Aug; 5(8):e2227211. PubMed ID: 35976648
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
